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SUMMARY 
The glucose-6-phosphate dehydrogenase-encoding gene (G6PD) belongs to a group with constitutive expression in all 
tissues. The regulation of these housekeeping genes is poorly understood, as compared to what is known about many 
genes whose expression is restricted to a particular tissue or stage of development, and which are often regulated by 
locus control regions (LCR) able to act over wide distances. In order to identify sequences in human G6PD which are 
necessary for its expression, we have generated transgenic mice carrying a 20-kb G6PD construct, including only 2.5 kb 
of upstream and 2.0 kb of downstream flanking sequence. All mice which carried the transgene (TG) expressed it, and 
the levels of expression detected in a range of tissues from three independent lines of mice were comparable to that of 
the endogenous murine G6PD. The variation in enzyme activity from tissue to tissue was remarkably similar for 
both the TG and the endogenous gene, and was shown to be due in both cases to variations in the steady-state 
mRNA levels. 
INTRODUCTION 
The X-linked human G6PD gene is a typical house- 
keeping gene, point mutations in which cause red cell 
G6PD deficiency, a common human enzymopathy asso- 
ciated with protection against malaria (Vulliamy et al., 
1992; Ruwende et al., 1995). Although ubiquitous, the 
expression of G6PD is not uniform; basal activity varies 
from one tissue to another and is also regulated within 
individual tissues (reviewed in Kletzien et al., 1994) 
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Several elements necessary for the basic expression of the 
X-linked human G6PD gene are known. Functional 
analysis of the GC-rich, 5’ region has revealed that the 
proximal 140 bp upstream from the transcription start 
point (tsp) constitutes the minimal promoter (Ursini et al., 
1990; Philippe et al., 1994). 
Very little is known of the molecular mechanisms regu- 
lating the levels of G6PD expression in different tissues. 
The analysis of tissue restricted genes has pointed out 
transcription as the step at which most regulation occurs 
G6PD, glucose-6-phosphate dehydrogenase; G6PD, gene encoding 
G6PD; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GAPDH, 
gene encoding GAPDH; kb, kilobase or 1000 bp; IU, international 
unit(s) (of G6PD activity); LCR, locus control region(s); NADP and 
NADPH, nicotinamide-adenine dinucleotide phosphate and its reduced 
form; NTG, non-transgenic; nt, nucleotide(s); PCR, polymerase chain 
reaction; Sp 1, stimulatory protein 1; SSC, 0.15 M NaCl/O.OlS M 
Na,citrate pH 7.6; TG, transgenic or transgene(s); tsp, transcription 
start point. 
242 
and has revealed the importance of LCRs, c&acting ele- 
ments able to regulate homologous transcriptional units 
distributed in ranges up to 100 kb (review&d in Dillon 
and Grosveld, 1993). Such an LCR is located a few 
hundred kb downstream from G6PD and controls the 
retina-specific expression of the red/green color vision 
gene cluster (Wang et al., 1992). More importantly, G6PD 
is part of a highly gene-dense region characterized by 
CpG islands associated with ubiquitously expressed 
genes (Bione et al., 1993). Therefore, as a first step 
towards understanding the tissue-specific regulation of 
the G6PD gene we aimed to delimit the region containing 
&-active elements and, to this end, we have produced 
TG mice containing the complete human G6PD gene, 
including 2.5 kb of 5’ and 2 kb of 3’ flanking sequence. 
EXPERIMENTAL AND DISCUSSION 
(a) Production of TG (transgenic) lines 
Transgenic (TG) mouse lines were generated using a 
20-kb human genomic DNA construct containing the 
G6PD gene. The construct, designated Gd15 contains the 
entire G6PD gene including 2.5 kb of upstream flanking 
sequence and 2.0 kb of downstream flanking sequence 
(Fig. 1). After removal of vector sequences the DNA was 
injected into the male or female pronuclei of oocytes 
freshly prepared from CB3 mice. Two sessions of injection 
yielded a total of 81 progeny of which nine were shown 
to carry the human G6PD gene by DNA amplification 
of tail biopsy DNA using specific primers. The presence 
of the TG in the PCR-positive mice was confirmed by 
Southern blotting. One founder mouse died and the 
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Fig. 1. Human G6PD construct used for microinjection. The TG used 
(Gd15) spanned 20105 bp of the human G6PD locus. In the cloned 
construct, the flanking EcoRI sites have been converted to Not1 sites. 
Methods: A pBluescript (Stratagene, La Jolla, CA, USA) sub-clone con- 
taining the 5’ 11.7-kb EcoRI genomic G6PD fragment was cut with 
EcoRV in the vector just upstream from the 5’ G6PD EcoRI site, 
trimmed with BAL31, ligated to Not1 linkers and cut with EcoRI + Not1 
to generate an EcoRI-Not1 insert; another sub-clone containing the 3’ 
4.9-kb genomic G6PD EcoRI fragment was cut with Hind111 in the 
vector just downstream from the 3’ G6PD EcoRI site, filled in, ligated 
with Not1 linkers and cut with EcoRI + Not1 to generate another EcoRI- 
Not1 insert; a sub-clone containing a 3.5-kb EcoRI fragment from the 
middle portion of the G6PD gene was isolated from pUC18 by EcoRI 
restriction. The three inserts thus generated were ligated together into 
a NotI-cut, phosphatase-treated pBluescript vector to generate Gd15. 
For microinjection, the TG was isolated from the vector by Not1 
digestion. 
remaining eight were mated with NTG (non-transgenic) 
mice to establish TG lines; three of the founders were 
capable of transmitting the TG to their offspring and 
three lines, designated PF5, PF8 and PF17 were estab- 
lished. DNA samples from the tails of mice from each of 
the lines were subjected to restriction analysis by 
Southern blotting using radioactively-labelled probes 
from human G6PD genomic DNA or cDNA (DNA com- 
plementary to RNA). The pattern of labelled bands, and 
their relative intensities measured by phophorimaging, 
were used to deduce the arrangement and copy number 
of the TG in each mouse line. In all lines TG were 
arranged in tandem, head to tail orientation. PF5 had 
three and PF17 had five complete copies. PF8 had two 
complete copies and a third incomplete copy with 5 kb 
deleted from its 5’ end (data not shown). 
(b) TG expression in the peripheral blood of potential 
founder mice 
We used the fact that G6PD is expressed in adult blood 
cells to rapidly assay all potential founder mice for TG 
expression. Samples of peripheral blood (50 ~1) were 
taken from mice carrying the TG, and cell lysates were 
prepared to assay G6PD activity. Lysate activities were 
measured spectrophotometrically and aliquots contain- 
ing 0.012 units of G6PD were run on cellulose acetate 
gels. After sufficient separation of the molecules, the gels 
were stained for G6PD activity; in each case, they show 
the mouse enzyme as a fast-running band, the human 
enzyme made by the TG as a slow-running band and a 
mouse/human hybrid protein with intermediate mobility 
(Fig. 2). All mice previously shown by PCR and Southern 
analysis to be carrying the TG also expressed it, and the 
level of enzyme activity attributable to the TG was always 
similar to the endogenous mouse G6PD activity. It is 
interesting to note that in the founder mice the mouse 
and human G6PD homodimer bands are often stronger 
than the heterodimer, implying that levels of mouse and 
human G6PD vary between individual cells (those 
making predominantly one type accounting for the 
homodimers), i.e., that the founder mice are mosaics. This 
phenomenon is less pronounced in the founders from 
which TG lines were obtained, PF5, PF8 and PF17. This 
level of mosaicism and failure to transmit the TG is rather 
higher than that found in most TG mouse experiments. 
(c) Mouse and human GBPD activity in TG mouse tissues 
Lysates were prepared from the tissues of TG and 
NTG mice and G6PD activity was measured by 
following the production of NADPH on a spectropho- 
tometer at 340 nm. In NTG mice, any measured activity 
was due to the endogenous murine enzyme. In mice from 
the TG lines the activity measured was the sum of the 
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Fig. 2. Cellogel analysis of G6PD activity in peripheral blood samples of potential founder mice carrying the G6PD TG. Lysates were prepared from 
50 ~1 samples of peripheral blood taken from mice carrying the human G6PD gene as a result of pronuclear micro-injection, and from human (Hu) 
and non-transgenic mouse (NTG) controls. The lysates were analysed on cellogels and stained for G6PD activity. The band running more slowly 
than the G6PD enzymes is haemoglobin. Methods: The method for the electrophoresis of lysates was a modification of that described previously 
(Rattazzi et al., 1967). Cellogel strips (Whatman) were equilibrated by gentle shaking for 15 min at room temperature in 100 ml of buffer (84 mM 
Tris.HCI pH 8.6/52 mM boric acid/l.8 mM EDTA) containing 20 FM NADP. The cellogel strips were placed in an electrophoresis tank containing 
the same buffer as above and lysates (t-10 ~1) were applied using a yellow pipetman tip. Electrophoresis was carried out at 4°C for 75 min at 130 
V. After electrophoresis, the gels were removed from the tank and placed face down in a G6PD-specific staining buffer (0.1 M TrisHCl pH 8.0/2 mM 
MgCI,/O.l mg/ml NADP/O.Z mg glucose-6-phosphate/O.1 mg phenazine methosulfate/0.15 mg mtroblue tetrazolium; all per ml). m, hy and h indicate 
the positions of the mouse G6PD homodimer the mouse/human (hy = hybrid) heterodimer and the human homodimer, respectively. 
activities of the enzymes encoded by the endogenous gene 
and the introduced genes. The results (Table I) show a 
clear increase in G6PD activity in all the tissues of the 
TG mice; the increase is consistently greater for line PF17 
which contains 5 copies than in either of the other two 
lines which have a lower copy number. 
In addition, the active enzyme was visualized after elec- 
trophoresis on cellulose acetate gels and subsequent 
staining. In these experiments a constant amount (0.012 
TABLE I 
G6PD specific activity in tissue lysates from NTG and TG mice 
Tissue” Mouse line 
NTG PF5 PF8 PF17 
G6PD activity (IU/g protein)b 
Liver to.o* 1.3 26.0 k 0.0 18.6k3.8 57.2+21.8 
Lung 41.0&0.1 144.1k31.1 139.3k40.1 247.9k138.4 
Brain 55.4k20.9 172.0f20.3 162.2k62.8 319.3k41.1 
Colon 64.8 + 26.5 106.3 k 3.5 102.4 k 24.0 200.5 f 105.0 
Heart 10.6k2.4 35.8 k 8.4 22.1+ 6.8 70.3 +37.3 
Kidney 48.4* 8.9 167.3 i 100.8 124.3 k 35.1 308.3 k74.3 
Skel. muscle 8.5 k 1.3 15.9i8.1 25.8 f 9.4 49.1+ 25.5 
Uterus 116.Oi23.0 202.6k54.3 292.9k200.4 715.1k436.4 
Spleen 82.8i24.6 151.9k36.5 138.1k55.1 460.6k285.2 
Ovary 165.0+65.7 340.1+0.0* 328.6k3.0 229.7+0.0* 
a The preparation of lysates from frozen mouse tissues was as described 
in the legend to Fig. 3. 
b Values are means i-standard deviation; n= 3 mice in each group, 
except * = 1 mouse only. 
IU = International units of enzyme activity. 
G6PD activity was assayed as described previously (Calabro et al.. 
1993). 
laboratory units) of GGPD activity was loaded in each 
lane so the relative amounts of staining of the human 
and murine bands reflect the contribution of each to the 
total enzyme activity in the tissue. In the different lines 
and in the different tissues (Fig. 3), the human enzyme 
was expressed at levels at least as high as the endogenous 
mouse enzyme. Within each line, the ratio of human to 
murine G6PD was similar in the different tissues, suggest- 
ing that tissue-specific variations in the regulation of the 
murine gene were mirrored in the human gene. There was 
one exception ~ in the colon, the human enzyme was 
consistently expressed at relatively lower levels with 
respect to the endogenous enzyme. The increased activity 
of human G6PD in line PF17 over lines PF5 and PF8, 
suggested by the measurement of total activity is clearly 
observed in the cellogel analysis as an increase in the 
proportion of enzyme activity in the human over the 
murine dimer. 
(d) Mouse and human CtiPD mRNA levels in TG mouse 
tissues 
The steady-state mRNA levels in TG mouse tissues 
were examined by Northern blotting. It was possible to 
compare the levels of mRNA from the endogenous mouse 
G6PD gene with those from the human G6PD transgene 
by using species specific probes; these were fragments 
from the 3’ non-coding regions of the genes and were 
270 bp and 160 bp long from the human and the mouse 
genes, respectively. 
In the three lines PF8, PF17 and PF5 the mRNA from 
a range of tissues from different mice was analysed. 
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Fig. 3. Cellogel analysis of G6PD activity in a range of tissues from three lines of TG mice carrying the human G6PD gene. Lysates were prepared 
from tissues of mice from each of three TG lines carrying the human G6PD gene. The lysates were analysed on cellogels and stained for G6PD 
activity; the arrows show the direction in which the gels were run. Methods: Frozen tissues were homogenized in 2-3 vols of G6PD lysis buffer in a 
Dounce homogenizer on ice, the homogenate was centrifuged at 13 000 rpm for 20 min at 4”C, and clear supernatants were transferred to new tubes 
and kept on ice. The methods used for cellogel analysis are described in the legend to Fig. 2. 
PF8 PF 17 PF5 
-human GAPDH 
Fig. 4. G6PD mRNA expression in a range of tissues from three lines of TG mice carrying the human G6PD gene. Total RNA was prepared from 
the frozen tissues of mice representing the TG lines PFS, PF17 and PF5. 10 pg of each sample were fractionated by electrophoresis in 1.25% agarose, 
blotted to nylon filters and hybridized at 42°C with radioactively-labelled probes to detect mRNA for mouse and human G6PD (2.2 kb) and for 
GAPDH (1.3 kb). The filters were washed in 2 x SSC (GAPDH) or 0.2 x SSC (G6PD) at 42°C and exposed to Kodak XAR5 film. 0.25 pg of each sample 
were visualized on ethidium bromide-stained mini-gels (1% agarose) to evaluate the amount and integrity of the material from the 28s (- 5000 nt) 
and 18s (approx. 1900 nt) rRNA bands, and samples from NTG littermates and from HeLa cells were included in the analysis to demonstrate the 
species specificity of the probes. For the PF8 Northern shown the human G6PD probe was labelled to a specific activity of 5.9 x lo8 cpm/pg and 
exposure time was 24 h; the mouse G6PD probe was labelled to a specific activity of 6.3 x 10’ cpm/pg and exposure time was 96 h; GAPDH probe, 
2.8 x 10’ cpm/pg, 24 h. For the PF17 Northern the figures were; human probe, 0.8 x 10’ cpm, 120 h; mouse probe, 0.5 x 10’ cpm/pg, 144 h; GAPDH 
probe, 14 x 10’ cpm/Fg, 6 h. For the PF5 Northern; human probe,4.5 x 10’ cpm/pg, 24 h; mouse probeJ.3 x 10’ cpm/pg, 144 h; GAPDH probe,14 x lo8 
cpm/pg, 6 h. Methods: RNA extraction was carried out by the method of Chirgwin et al. (1979). Northern blotting was carried out as described 
previously (Mason et al., 1993). Probes used for Northern blotting were: human G6PD, a 270-bp genomic XhoI fragment from the 3’ non-coding 
region; murine G6PD, a 160-bp XbaI-EcoRI fragment from a cloned portion of the 3’ non-coding region of the mouse G6PD gene; human GAPDH, 
a 777-bp genomic BamHI fragment. 
Representative Northern blots (Fig. 4) show that the 
variation in mouse G6PD mRNA levels between tissues 
is similar to the variation in G6PD activity with uterus 
and ovary having the highest levels and heart and liver 
the lowest. In each mouse, the TG was expressed in all 
of the tissues examined and the pattern of expression of 
the TG mRNA from tissue to tissue was almost indistin- 
guishable from the pattern of expression of the endoge- 
nous murine G6PD mRNA; the ratio of human G6PD 
mRNA to murine G6PD mRNA was similar in the 
different tissues. There was one exception ~ the ratio of 
human to murine G6PD mRNA was lower in the colon 
than in any of the other tissues, and this difference was 
consistent in each of the mice analysed. The specificity of 
the human and murine probes was demonstrated by rou- 
tinely including one track of NTG murine mRNA and 
one track of human mRNA on the filters. After auto- 
radiography and phosphorimaging, the filters were 
stripped prior to re-hybridization with a probe for 
human GAPDH. 
In all mice examined the steady-state mRNA level per 
gene copy was to a first approximation similar for the 
human TG and the endogenous mouse gene. For example 
in the experiment on line PF8 shown in Fig. 4 the human 
and mouse bands are of equal intensity. The exposure 
time with the human probe is a quarter of that with the 
mouse probe while the human probe is twice as long and 
there are two copies of the human gene. Since the specific 
activity of both probes is similar, the human and mouse 
mRNA levels per gene copy are approximately equal. 
(e) The tsp of the human gene in TG mice 
To verify that the mRNA levels and enzyme activities 
encoded by the human TG were due to activity of the 
human promoter, we determined the tsp of human G6PD 
mRNA from TG mouse tissues by Sl nuclease mapping. 
The result (Fig. 5) shows that the cap site of the human 
mRNA in mouse tissues is the same as in normal human 
fibroblasts. 
(f ) Conclusions 
(I) Although the G6PD gene is located in a gene dense 
region of Xq28 along with several other housekeeping 
genes all the &-acting regulatory elements seem to be 
within the 20-kb region containing the structural gene 
and its immediate flanking sequences. The construct was 
expressed in all of the founder mice and TG lines exam- 
ined at levels which were at least as high as the endoge- 
nous gene - strong evidence that the TG expression was 
unaffected by its position of integration. The expression 
of the TG increased with a higher TG number - though 
the range of copy numbers was narrow. Tissue-specific 
Fig. 5. Mapping the tsp of the human G6PD TG in normal human 
fibroblasts and in TG kidney. Total RNA was isolated from the kidney 
of a mouse from the TG line PF17 and from the human fibroblast cell 
line MRC 5. Samples were hybridized at 65°C to the radioactively- 
labelled mapping probe pHB, digested with Sl nuclease at 13°C for 60 
min, and analyzed on a 6% polyacrylamide gel. Lanes: control - no 
RNA included ( l), control - no RNA included/no Sl nuclease treatment 
(2) 5.0, 2.5 and 0.5 ug TG kidney RNA (3, 4 and 5); 5.0, 2.5 and 0.5 ug 
human fibroblast RNA (6, 7 and 8) TaqI + PuuII-digested pEMBL size 
markers (M; sizes in bp: 1008, 613, 357, 278, 193, 108). Methods: Sl 
mapping was carried out by standard procedures (Mason et al., 1993) 
using as probe a single-stranded 158-bp HaeII-BamHI DNA fragment 
(pHB) spanning the normal tsp in the human G6PD gene. The probe 
was prepared from p5B, a cDNA clone which extends into the promoter 
region beyond the most commonly used cap site (Martini et al., 1986). 
variation in expression was similar for the TG and the 
endogenous mouse G6PD. 
(2) For the G6PD activity of both mouse and human, 
it was found that the variations in enzyme activity mea- 
sured from one tissue to another were mirrored by varia- 
tions in the steady-state mRNA levels. This suggests that 
tissue-specific regulation of the G6PD gene occurs at 
either the rate of synthesis or degradation of mRNA, and 
not at the translational or post-translational levels. 
(3) In the colon, the expression differed from the other 
tissues in that there was consistently a relative deficiency 
of human G6PD mRNA and enzyme. Either this could 
be because of a real species-specific difference in colon 
specific G6PD expression or some colon-specific regula- 
tory element has not been included in the introduced 
construct. The high levels of expression in all other tissues 
examined, and their similarity to the endogenous expres- 
sion levels would tend to favour the first possibility. 
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